Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6383869 | 0.92 | P2RX3 (0.35) | — | |
| SCHEMBL6383876 | 0.87 | — | — | |
| SCHEMBL2962650 | 0.81 | ALDH1A1 (0.38) | POLBGAANPSR1ALDH1A1HSD17B10 | |
| SCHEMBL5772759 | 0.81 | PDE4A (0.35) | ELANEPRTN3POLBGAANPSR1 | |
| SCHEMBL23146029 | 0.80 | KMT2A (0.41) | POLBGAANPSR1ADORA3ALDH1A1 | |
| SCHEMBL5718924 | 0.80 | BACE1 (0.41) | ADORA3 | |
| SCHEMBL6409570 | 0.73 | MAOB (0.38) | GAANPSR1ADORA3ALDH1A1HSD17B10 | |
| SCHEMBL5719066 | 0.73 | BACE1 (0.36) | GAAADORA3 | |
| SCHEMBL2964029 | 0.73 | KMT2A (0.37) | POLBGAANPSR1ALDH1A1HSD17B10 | |
| SCHEMBL29850138 | 0.72 | CNR1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | ELANE 2327/4885PRTN3 1061/4885POLB 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.